Last 47 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -32.20 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 15.40 | 12.74 | 14.48 | 22.70 | 20.27 | 49.37 | 56.58 | 358.33 | 147.85 | 151.96 | 111.79 | 27.64 | 30.91 | 86.09 | 62.49 | 56.62 | 61.50 | 32.44 | 68.15 | 65.30 | 54.18 |
| — | -74.2% | -74.4% | -93.7% | -86.3% | -67.5% | -49.4% | +1196.2% | +378.3% | +76.5% | +78.9% | -51.2% | -49.7% | +165.4% | -8.3% | -13.3% | +13.5% | -73.3% | -47.8% | -41.3% | -87.1% | |
| P/B Ratio | 3.25 | 3.09 | 3.51 | 4.06 | 3.62 | 2.32 | 2.66 | 4.90 | 2.02 | 1.59 | 1.17 | 0.37 | 0.41 | 1.47 | 1.01 | 0.90 | 0.68 | 0.58 | 1.06 | 1.16 | 1.39 |
| — | +33.1% | +32.0% | -17.3% | +79.0% | +45.9% | +127.3% | +1231.7% | +391.4% | +8.4% | +16.4% | -58.9% | -39.4% | +152.8% | -5.2% | -22.8% | -51.2% | -65.1% | -36.3% | -39.5% | -65.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 9.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.1% | 143.2% | 143.2% | -4.7% | -4.7% | -231.1% | -231.1% | -107.8% | -107.8% | -762.3% | -762.3% | -472.4% | -472.4% | -620.9% | -586.5% | -686.7% | -635.3% | -623.0% | -588.2% | -604.8% | -369.3% |
| — | +161.9% | +161.9% | +95.6% | +95.6% | +69.7% | +69.7% | +77.2% | +77.2% | -22.8% | -30.0% | +31.2% | +25.6% | +0.3% | +0.3% | -13.5% | -72.0% | -3.0% | +37.0% | +26.7% | +82.4% | |
| Operating Margin | -42.6% | 133.9% | -59.5% | -150.2% | -150.2% | -489.5% | -489.5% | -1306.7% | -1306.7% | -1750.7% | -1750.7% | -1184.6% | -1184.6% | -891.9% | -745.9% | -1066.3% | -1109.1% | -890.6% | -961.7% | -932.8% | -534.4% |
| — | +127.3% | +87.8% | +88.5% | +88.5% | +72.0% | +72.0% | -10.3% | -10.3% | -96.3% | -134.7% | -11.1% | -6.8% | -0.1% | +22.4% | -14.3% | -107.5% | +7.9% | +29.0% | +20.7% | +80.6% | |
| Net Margin | -47.8% | -25.2% | -25.2% | -78.2% | -78.2% | -386.0% | -386.0% | -1518.8% | -1518.8% | -2204.3% | -2204.3% | -960.4% | -960.4% | -1024.7% | -959.3% | -1236.7% | -1170.1% | -964.7% | -1059.3% | -1089.2% | -630.1% |
| — | +93.5% | +93.5% | +94.8% | +94.8% | +82.5% | +82.5% | -58.1% | -58.1% | -115.1% | -129.8% | +22.3% | +17.9% | -6.2% | +9.4% | -13.5% | -85.7% | +12.7% | +23.6% | +5.2% | +66.9% |
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.9% | -1.5% | -1.5% | -3.5% | -3.4% | -4.5% | -5.1% | -5.2% | -5.1% | -5.8% | -5.6% | -3.2% | -3.2% | -4.5% | -3.8% | -4.8% | -3.3% | -4.2% | -4.0% | -4.7% | -4.0% |
| — | +66.4% | +70.4% | +32.8% | +32.7% | +21.4% | +8.6% | -62.5% | -58.1% | -29.5% | -47.9% | +33.2% | +2.8% | -5.3% | +6.4% | -1.1% | +16.6% | -13.4% | +14.5% | +2.5% | +12.0% | |
| ROA | -7.4% | -1.1% | -1.1% | -2.6% | -2.6% | -3.5% | -3.8% | -3.7% | -3.6% | -4.1% | -4.1% | -2.4% | -2.4% | -3.3% | -2.8% | -3.6% | -2.5% | -3.2% | -3.1% | -3.6% | -3.1% |
| — | +67.5% | +70.4% | +30.0% | +29.3% | +16.6% | +8.9% | -51.1% | -49.2% | -24.7% | -46.6% | +33.0% | +3.1% | -4.0% | +8.2% | +0.5% | +18.8% | -9.3% | +15.8% | +0.9% | +9.0% | |
| ROIC | -6.4% | 5.8% | -2.6% | -5.0% | -5.1% | -4.6% | -4.6% | -2.8% | -2.8% | -3.1% | -3.0% | -2.7% | -2.7% | -2.6% | -2.0% | -2.9% | -2.2% | -2.7% | -2.7% | -3.0% | -2.6% |
| — | +227.7% | +43.4% | -77.1% | -77.5% | -48.5% | -52.9% | -3.2% | -3.9% | -17.8% | -52.6% | +6.0% | -24.6% | +4.2% | +25.4% | +4.7% | +15.9% | -3.2% | +25.6% | +17.3% | +48.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | 0.22 | 0.24 | 0.24 | 0.21 | 0.21 | 0.27 | 0.27 | 0.25 | 0.25 | 0.24 | 0.23 | 0.23 | 0.24 | 0.22 | 0.21 | 0.22 | 0.20 | 0.19 | 0.19 |
| — | +4.4% | +4.4% | -14.0% | -14.0% | -13.4% | -13.4% | +14.0% | +16.7% | +6.6% | +4.2% | +7.3% | +11.7% | +7.9% | +17.5% | +16.0% | +9.5% | +18.5% | +19.4% | +0.2% | +2.1% | |
| Debt / EBITDA | — | 2.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.43 | 2.43 | 2.43 | 1.58 | 1.58 | 1.99 | 1.99 | 0.96 | 0.96 | 1.18 | 1.18 | 2.71 | 2.71 | 1.95 | 1.14 | 1.43 | 1.90 | 1.36 | 1.69 | 1.88 | 1.36 |
| — | +22.3% | +22.3% | +65.1% | +65.1% | +68.7% | +68.7% | -64.7% | -64.7% | -39.3% | +3.7% | +89.6% | +42.5% | +43.1% | -32.6% | -23.7% | +40.2% | -13.5% | -2.0% | +88.9% | +3.0% | |
| Quick Ratio | 2.09 | 2.09 | 2.09 | 1.41 | 1.41 | 1.77 | 1.77 | 0.63 | 0.63 | 1.18 | 1.18 | 2.71 | 2.71 | 1.95 | 1.05 | 1.33 | 1.90 | 1.36 | 1.69 | 1.88 | 1.36 |
| — | +17.7% | +17.7% | +125.8% | +125.8% | +50.3% | +50.3% | -77.0% | -77.0% | -39.3% | +12.1% | +104.8% | +42.5% | +43.1% | -37.6% | -29.4% | +40.2% | -13.7% | -1.7% | +88.9% | +3.6% | |
| Interest Coverage | -2.15 | — | — | -2.51 | -2.51 | — | — | -1.87 | -1.87 | -3.63 | -3.63 | -2.61 | -2.61 | -4.82 | -2.74 | -3.18 | -2.72 | -3.94 | -4.06 | -4.08 | -4.48 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MESO stock.
Mesoblast Limited's current P/E is -32.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Mesoblast Limited's current operating margin is -42.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Mesoblast Limited's business trajectory between earnings reports.